Skip to content
Markets News
Earnings1 min read

Bayer lifts 2026 profit range after pharma sales beat estimates

Makkler Newsroom
November 3, 2026 · Based on reporting by finanzen.net, The Economic Times

The company raised its earnings outlook after third-quarter pharmaceutical sales exceeded analysts’ expectations and lowered its full-year debt forecast.

Key takeaways

  • Bayer now expects 2026 adjusted core earnings of 9.8 billion to 10.3 billion euros.
  • Third-quarter pharmaceutical sales reached 4.68 billion euros, 5% above analysts’ expectations.
  • Bayer shares traded at 52.94 euros, up 5.84% since the previous close.

Bayer raised its 2026 adjusted core earnings forecast to between 9.8 billion and 10.3 billion euros on a currency-adjusted basis. The German group cited stronger-than-expected pharmaceutical performance.

The division reported third-quarter sales of 4.68 billion euros, beating analysts’ expectations by 5%, according to a Vara Research poll. CEO Bill Anderson said the business had reached an important turning point in its growth trajectory.

Bayer also lowered its full-year net financial debt forecast by 1 billion euros, to a range of 28 billion to 29 billion euros. As of 09:12 UTC on Tuesday, shares traded at 52.94 euros, up 5.84% since the previous close.

Topics
Further reading

This article was produced with the help of AI technology. Based on reporting by the outlets listed above.

Comments (0)

Log in to join the discussion.Log in

No comments yet - be the first to weigh in.